The reformed EU pharmaceutical legislation tightens obligations around shortages, while EMA is expanding the European Shortages Monitoring Platform. Companies should treat shortage management as a regulatory process, not just a supply chain task.
What the reform brings
Law firm analyses of the final texts indicate that shortage monitoring and management provisions, including notifications and shortage prevention plans, apply roughly six months after entry into force. If the Official Journal publication takes place at the end of 2026, that points to the first half of 2027.
The digital layer
In welcoming the political agreement on the Critical Medicines Act, EMA said it is expanding the European Shortages Monitoring Platform, a tool designed to allow faster, data-driven exchange between industry and regulators on potential shortages. Industry data quality will determine how useful that exchange is.
Practical readiness steps
- Map critical products. Identify products where interruption would harm patients or where single sources exist.
- Define triggers. Agree internal thresholds for early warning, not just actual stock-outs.
- Document prevention plans. Record dependencies, safety stock, alternative sources and mitigation options.
- Assign responsibility. Link regulatory affairs, quality and supply planning with a named owner for notifications.
National overlay
EU duties sit alongside national notification and export rules. In Greece, shortage and parallel export management is already an active policy topic, so national and EU processes should be designed together.
How PQRA helps
PQRA helps marketing authorisation holders design shortage notification procedures, prevention plans and governance, and align them with national reporting obligations and EU developments.


No responses yet